While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. Dual GLP-1/GIP agonists are considered promising new drugs for the treatment of obesity and type 2 diabetes.
This content is machine-translated. Please contact us if you need professional translation services.
- Mirjam Peter, M.Sc.
- HAUSARZT PRAXIS
You May Also Like
- Cardiovascular risk in IBD
- Microplastics in kidneys and urine
- Asthma and psyche
- 5 min
- COPD: Update for the primary care physician
- 6 min
- 7 min
- Atopic dermatitis: choice of systemic therapy option
- Do low carb diets harm the heart?
- 3 min
- Cardiovascular events in CKD